Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CING · NASDAQ · Pharmaceutical Preparations
$4.51−0.75 (−14.26%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Cingulate (CING) · oqro.io/stocks/CING · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Insider trade · Traded Feb 13, 2026 · Filed Jun 8, 2026
Director purchased ~$490K of CING shares in the open marketSourceInsider trade · Traded Feb 6, 2026 · Filed Feb 11, 2026
CEO purchased ~$34K of CING shares in the open marketSourceInsider trade · Traded Feb 6, 2026 · Filed Feb 11, 2026
Director purchased ~$98K of CING shares in the open marketSourceInsider trade · Traded Feb 6, 2026 · Filed Feb 11, 2026
CFO purchased ~$25K of CING shares in the open marketSourceInsider trade · Traded Feb 6, 2026 · Filed Feb 11, 2026
Officer purchased ~$9.8K of CING shares in the open marketSource